查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994189

癌症譜分析市場：2026-2032年全球市場預測（按癌症類型、技術、檢體類型、生物標記類型、應用和最終用戶分類）

Cancer Profiling Market by Cancer Type, Technology, Sample Type, Biomarker Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症分析市場價值將達到 131.1 億美元，到 2026 年將成長至 145.1 億美元，到 2032 年將達到 288.1 億美元，複合年成長率為 11.89%。

主要市場統計數據
基準年 2025 131.1億美元
預計年份：2026年 145.1億美元
預測年份：2032年 288.1億美元
複合年成長率 (%) 11.89%

本文簡要概述了癌症分析領域的最新技術、臨床和營運趨勢，為診斷和治療領域的相關人員提供策略決策指南。

本執行摘要整合了癌症分析技術、臨床應用和終端用戶採納趨勢的最新進展，旨在為診斷、治療和研究領域的相關人員提供策略規劃支援。摘要重點在於技術創新與臨床需求的交匯點，揭示了不斷發展的檢測能力、檢體工作流程和生物標記策略如何重塑診斷決策和轉化研究路徑。

定序、非侵入性取樣和綜合生物標記策略的快速創新如何重新定義癌症分析的臨床工作流程和商業性夥伴關係？

定序精度、多重檢測和檢體獨立分析模型的顯著進步正在變革癌症譜分析，拓展臨床醫生可採取的實用決策範圍。長讀長和短讀長定序技術整合到診斷流程中，能夠捕捉以往難以檢測的複雜基因組重排和結構突變，從而實現對腫瘤生物學特徵和抗藥性機制更精細的分層分析。

本文展望了 2025 年的關稅措施將如何重塑癌症診斷和研究領域中相關人員的供應鏈、定價趨勢和策略採購選擇。

將於2025年實施的新關稅措施將對癌症基因分型相關人員產生多方面的影響，包括供應鏈、籌資策略和跨境合作。對於定序儀和檢測試劑盒的製造商而言，某些組件和成品進口關稅的提高可能會推高整體成本，迫使供應商重新評估其定價、採購和庫存管理策略。這一趨勢將促使診斷實驗室和醫院重新評估其試劑採購週期，並協商在不影響臨床能力的前提下，維持高價值檢測資源供應的合約。

細分市場分析揭示了癌症類型、技術選擇、檢體基質、生物標記分類、應用和最終用戶需求如何共同決定臨床和商業性優先事項。

透過細分獲得的洞見揭示了臨床效用、技術成熟度和最終用戶需求之間的交集，從而在癌症譜分析的整體情況中創造了機會和風險。基於癌症類型，骨髓惡性腫瘤和固態腫瘤之間的差異導致了不同的檢測重點。血液系統惡性腫瘤的工作流程著重於檢測白血病、淋巴瘤和多發性骨髓瘤的特定融合事件、克隆動態和微量殘存疾病，而固態腫瘤譜分析則著重於乳癌、結直腸癌、肺癌和前列腺癌中治療關鍵突變和腫瘤異質性。這些不同的臨床目標決定了檢查室操作中的檢測方法選擇、檢體處理和報告細節。

區域觀點下的部署管道、監管差異以及影響癌症分析解決方案公平取得和推廣的基礎設施要求。

區域趨勢對全球癌症基因譜分析的可及性、應用率和策略重點起著至關重要的作用。在美洲，對精準腫瘤學基礎設施的投資、下一代測序技術的廣泛應用以及整合醫療網路的建設，都為新型檢測方法的快速臨床應用提供了支持；與此同時，市場參與企業必須應對複雜的報銷機制和檢查室認證的差異。該地區通常在醫療設備製造商和製藥公司之間的伴隨診斷合作中發揮主導作用，從而形成豐富的研發管線，用於進行實施研究和產生真實世界數據（REW）。

伴隨診斷領域的策略專業化、整合服務模式和合作夥伴關係如何定義競爭優勢並實現可擴展的臨床部署？

主要企業和研究機構正透過結合專業化、垂直整合服務、檢測方法開發和資訊學以及臨床支援的合作模式來脫穎而出。一些公司專注於平台卓越性，提供檢驗的儀器、耗材和標準化的工作流程，從而實現高性能診斷；而其他公司則專注於特定臨床應用，例如微量殘存疾病檢測和複雜結構突變的解析。技術提供者與製藥開發公司之間的策略夥伴關係日益普遍，將伴隨診斷的開發與治療產品線相結合，以簡化監管核准和市場准入流程。

為領導者制定可操作的策略重點，以加速分析解決方案的部署和管理，建立供應鏈彈性、臨床檢驗路徑和互通服務。

產業領導者應優先投資於能夠增強韌性、臨床有效性和與醫療服務路徑無縫整合的領域。提高供應鏈透明度和採購柔軟性可以降低關稅和物流風險，而對本地製造和分銷的定向投資可以縮短前置作業時間，並確保關鍵耗材的穩定供應。同時，各機構應投資跨平台檢驗研究，以證明不同技術的兼容性，並支援電子醫療系統間臨床報告的互通性。

透過與專家對話、整合技術文獻以及與檢查室標準交叉檢驗，高度透明且以實踐者為中心的調查方法確保了實用見解。

本執行摘要的調查方法結合了第一手和二級資訊來源、專家訪談以及結構化的綜合分析，旨在對技術、臨床和商業性趨勢進行平衡評估。第一手資料包括與實驗室管理人員、臨床研究人員和行業高管的對話，以了解實際營運情況、證據要求和推廣應用障礙。除這些定性研究外，還仔細查閱了同行評審文獻、監管指南和技術白皮書，以支持技術說明和臨床應用定義。

最終的綜合分析將重點放在技術、證據和營運韌性之間的關鍵交互作用，從而確定哪些分析技術能夠產生持久的臨床影響。

總之，癌症基因分型正處於一個轉折點，技術進步、法規演進和供應鏈變化相互交織，既帶來了機遇，也帶來了營運挑戰。最成功的機構很可能將可靠的檢測技術與檢驗的工作流程、快速的供應策略以及以臨床醫生為中心的報告相結合，從而直接支持治療決策。為了將分析能力轉化為常規臨床應用，跨平台檢驗和證據產生至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 癌症譜分析市場：依癌症類型分類

  • 骨髓惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固體癌
    • 乳癌
    • 結腸癌
    • 肺癌
    • 攝護腺癌

第9章：癌症基因分型市場：依技術分類

  • 螢光原位雜合反應
  • 免疫組織化學
  • 微陣列
  • 下一代定序
    • 長讀長定序
    • 短讀定序
  • 聚合酵素鏈鎖反應

第10章 癌症基因譜分析市場：依檢體類型分類

  • 血
    • 電漿
    • 血清
    • 全血
  • 唾液
  • 尿

第11章 癌症譜分析市場：依生物標記類型分類

  • 基於DNA的
  • 基於蛋白質
  • 基於RNA的

第12章 癌症基因分型市場：依應用領域分類

  • 診斷
  • 監測
    • 液態生物檢體
    • 微量殘存疾病
  • 預後
  • 研究
  • 治療方法方案
    • 伴隨診斷
    • 藥物基因體學

第13章 癌症基因分型市場：依最終用戶分類

  • 診斷檢測實驗室
  • 醫院
  • 製藥公司
  • 研究機構

第14章 癌症基因分型市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 癌症基因分型市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 癌症基因分型市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國癌症基因分型市場

第18章：中國癌症基因檢測市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 4basecare Onco Solutions Private Limited
  • ACT Genomics Co., Ltd. by Prenetics Global Limited
  • Agendia, Inc.
  • Agilent Technologies, Inc.
  • BostonGene Corporation
  • Caris Life Sciences
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • GENINUS Inc.
  • Genomic Life
  • GenScript BIoTech Corporation
  • Guardant Health, Inc.
  • Hologic, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • IMBdx, Inc.
  • Laboratory Corporation of America Holdings
  • Lucence Health, Inc.
  • Merck KGaA
  • NanoString Technologies, Inc.
  • Neogenomics, Inc.
  • Nonacus Limited
  • OncoDNA SA
  • Oncompass Medicine Hungary Kft.
  • Paragon Genomics, Inc.
  • Personalis, Inc.
  • Perthera, Inc.
  • Qiagen NV
  • Renovaro Biosciences Inc.
  • Strand Life Sciences
  • Sysmex Corporation
  • Takara Bio Inc.
  • Tempus Labs Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-1A1A064C046A

The Cancer Profiling Market was valued at USD 13.11 billion in 2025 and is projected to grow to USD 14.51 billion in 2026, with a CAGR of 11.89%, reaching USD 28.81 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.11 billion
Estimated Year [2026] USD 14.51 billion
Forecast Year [2032] USD 28.81 billion
CAGR (%) 11.89%

A concise synthesis of recent technological, clinical, and operational dynamics in cancer profiling that frames strategic decisions for diagnostics and therapeutic stakeholders

This executive summary synthesizes contemporary developments in cancer profiling technologies, clinical applications, and end-user adoption trends to inform strategic planning for stakeholders across diagnostics, therapeutics, and research. It focuses on the intersection of technological innovation and clinical need, highlighting how evolving assay capabilities, sample workflows, and biomarker strategies are reshaping diagnostic decision-making and translational research pathways.

The narrative emphasizes practical implications for clinical laboratories, hospitals, pharmaceutical developers, and research institutions by integrating recent advances in next-generation sequencing, molecular assays, and liquid biopsy approaches with shifting supply chain dynamics and regulatory expectations. It situates these developments within broader healthcare imperatives such as precision oncology, molecularly informed therapy selection, and real-world evidence generation. The intent is to provide readers with a concise, actionable foundation for aligning investment, operational, and clinical strategies with the most impactful trends in cancer profiling today.

Through a combination of technology-focused analysis and end-user perspectives, the summary also identifies critical dependencies-such as reagent availability, sample handling standards, and data interpretation infrastructures-that will determine which innovations achieve routine clinical utility. The content is designed to be relevant for executives, clinical leaders, and laboratory directors seeking to weigh technology choices and partnership opportunities against evolving clinical demands and regulatory pathways.

How rapid innovations in sequencing, noninvasive sampling, and integrated biomarker strategies are redefining clinical workflows and commercial partnerships in cancer profiling

Cancer profiling is undergoing transformative shifts driven by leaps in sequencing fidelity, assay multiplexing, and sample-agnostic analytic models that expand the actionable window for clinicians. Advances in long-read and short-read sequencing modalities are being integrated into diagnostic pipelines to capture complex genomic rearrangements and structural variants that were previously elusive, enabling finer stratification of tumor biology and resistance mechanisms.

Concurrently, improvements in noninvasive sampling and liquid biopsy sensitivity are extending the utility of monitoring and minimal residual disease detection, while immunohistochemistry and fluorescence in situ hybridization continue to provide rapid, tissue-based context for therapeutic decisions. These technological refinements are supported by enhanced bioinformatics toolchains that reduce interpretive variability and accelerate turnaround times, fostering broader adoption among diagnostic laboratories and hospitals.

Parallel to laboratory innovations, the landscape is shifting toward modular workflows that prioritize interoperability, standardized reporting, and cross-platform validation. This movement is reinforced by stakeholders' demand for companion diagnostics and pharmacogenomic insights that directly inform therapy selection, driving closer collaboration between assay developers and pharmaceutical companies. As a result, the paradigm is moving from isolated tests toward integrated diagnostic ecosystems that combine DNA-based, RNA-based, and protein-based biomarkers to deliver multidimensional clinical intelligence.

Finally, the cumulative effect of these shifts is altering value propositions across the care continuum: early and accurate molecular characterization reduces diagnostic odysseys, enables targeted enrollment into clinical trials, and supports adaptive treatment strategies. The implication for market participants is clear: success will depend on delivering reproducible, clinically actionable results at scale, supported by robust logistics, compliant data governance, and sustainable commercial models that align incentives across providers, payers, and developers.

Anticipating how 2025 tariff measures reshape supply chains, pricing dynamics, and strategic sourcing choices for cancer profiling stakeholders across diagnostics and research

The introduction of new tariff measures in the United States in 2025 presents a multifaceted set of implications for cancer profiling stakeholders, affecting supply chains, procurement strategies, and cross-border collaboration. For manufacturers of sequencing instruments and assay kits, increased import duties on select components and finished goods can elevate landed costs, prompting suppliers to reassess pricing, sourcing, and inventory practices. This dynamic will exert pressure on diagnostic laboratories and hospitals to reevaluate reagent purchasing cycles and to negotiate contracts that preserve access to high-value assays without compromising clinical throughput.

Beyond direct cost effects, tariffs can catalyze strategic responses such as supplier diversification, nearshoring of critical manufacturing steps, and greater emphasis on regional distribution hubs to mitigate lead-time volatility. These adaptations may improve resilience in the medium term but require upfront capital and operational changes that can temporarily disrupt service delivery. In parallel, research institutes and pharmaceutical companies that depend on imported specialized reagents and instrumentation may face project delays or increased study costs, influencing timelines for biomarker validation and companion diagnostic development.

Tariff-driven price adjustments also have downstream implications for adoption of advanced technologies such as long-read sequencing or high-content platforms. Providers in resource-constrained settings may prioritize established, lower-cost methodologies like immunohistochemistry and polymerase chain reaction, slowing diffusion of higher-cost but clinically informative technologies. Conversely, payers and health systems may accelerate consolidation of testing within centers of excellence to preserve access to comprehensive profiling while containing overall expenditure.

On the regulatory and policy front, tariffs can prompt dialogue between industry and government about strategic importance of biotech supply chains, potentially accelerating incentives for domestic manufacturing, public-private partnerships, and targeted investments in local capacity. These policy responses may reduce long-term vulnerability but will also shape competitive dynamics and the distribution of manufacturing expertise globally. Collectively, the tariff environment underscores the importance of supply chain transparency, flexible sourcing strategies, and proactive stakeholder engagement to ensure continuity of high-quality cancer profiling services.

Segment-level analysis revealing how cancer type, technology choice, sample matrix, biomarker class, application purpose, and end-user requirements jointly determine clinical and commercial priorities

Insights derived from segmentation illuminate where clinical utility, technology maturity, and end-user needs converge to create opportunity and risk across the cancer profiling landscape. Based on cancer type, differences between hematologic malignancies and solid tumors drive distinct testing priorities: hematologic workflows emphasize detection of specific fusion events, clonal dynamics, and minimal residual disease across leukemia, lymphoma, and multiple myeloma, while solid tumor profiling concentrates on actionable mutations and tumor heterogeneity within breast, colorectal, lung, and prostate cancers. These divergent clinical goals inform assay selection, sample handling, and reporting granularity in laboratory operations.

Based on technology, the diagnostic toolkit spans fluorescence in situ hybridization, immunohistochemistry, microarray platforms, next-generation sequencing, and polymerase chain reaction. Within next-generation sequencing, the emergence of both long-read sequencing and short-read sequencing enables complementary interrogation of genomic complexity: short-read approaches provide high-throughput mutation detection and cost-efficiency, while long-read methods resolve structural variants and repetitive regions that have clinical relevance for specific tumor types. The choice of technology is shaped by clinical indication, turnaround time requirements, and the analytic sensitivity necessary for monitoring and early detection.

Based on sample type, blood, saliva, and urine each offer unique advantages and constraints. Blood-derived analyses-including plasma, serum, and whole blood-support both tumor genotyping and longitudinal monitoring via circulating tumor DNA, whereas saliva and urine present noninvasive alternatives for certain tumor types and patient populations. Sample matrices influence pre-analytical workflows, cold chain logistics, and interpretation frameworks, requiring laboratories to standardize collection protocols to preserve assay performance.

Based on biomarker type, DNA-based, protein-based, and RNA-based markers provide orthogonal insights that enhance diagnostic confidence and therapeutic alignment. DNA analyses excel at identifying somatic and germline variants; RNA-based assays reveal gene expression patterns and fusion transcripts; and protein-based measurements capture phenotypic states that can predict drug response. Integrating these biomarker classes into composite reports increases clinical actionability but demands harmonized validation and cross-platform comparability.

Based on application, diagnosis, monitoring, prognosis, research, and therapy selection define the primary use cases for profiling technologies. Monitoring use cases such as liquid biopsy and minimal residual disease require assays with exceptional sensitivity and reproducibility, while therapy selection relies on companion diagnostics and pharmacogenomics to match patients to targeted therapies and dosing strategies. Each application imposes different demands on assay design, regulatory documentation, and evidence generation.

Based on end user, diagnostic laboratories, hospitals, pharmaceutical companies, and research institutes exhibit distinct operational constraints and value drivers. Diagnostic laboratories prioritize throughput, reproducibility, and reimbursement pathways; hospitals focus on integration with clinical workflows and electronic health records; pharmaceutical companies seek robust biomarker validation and companion diagnostic alignment for drug development; and research institutes emphasize exploratory analyses and novel target discovery. Recognizing these user-specific imperatives is essential for tailoring product design, service models, and commercialization strategies.

A regional perspective on adoption pathways, regulatory variability, and infrastructure requirements that influence equitable access and scale-up of cancer profiling solutions

Regional dynamics play a decisive role in shaping access, adoption rates, and strategic priorities for cancer profiling across the globe. In the Americas, investments in precision oncology infrastructure, widespread adoption of next-generation sequencing, and integrated care networks support rapid clinical translation of novel assays, while market participants must navigate reimbursement complexity and heterogeneous laboratory accreditation landscapes. This region often leads in companion diagnostic collaborations between device makers and pharmaceutical sponsors, producing rich pipelines for implementation studies and real-world evidence generation.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable healthcare financing models create a patchwork of adoption scenarios that favor regionally tailored strategies. High-capacity centers in Western Europe act as hubs for advanced diagnostics and multicenter studies, whereas other subregions prioritize cost-effective assays and scalable workflows that can operate in constrained settings. Cross-border collaborations within Europe are increasingly important for harmonizing standards, enabling data sharing, and accelerating multicountry trials that validate biomarker utility across diverse populations.

In Asia-Pacific, rapid expansion of laboratory capacity, increasing public and private investment in genomics, and large patient populations present substantial opportunities for scaling both diagnostic services and biomarker-driven clinical research. Nevertheless, varying levels of regulatory maturity and differences in reimbursement create a landscape where local partnerships, technology transfer, and capacity building are critical to achieving broad access. Across all regions, supply chain considerations, workforce training, and data governance frameworks will determine the pace and equity of clinical implementation, making regionally informed strategies essential for sustained impact.

How strategic specialization, integrated service models, and collaborative companion diagnostic partnerships define competitive advantage and enable scalable clinical adoption

Leading companies and research organizations are differentiating through specialization, vertically integrated offerings, and collaborative models that combine assay development with informatics and clinical support. Some firms concentrate on platform excellence-delivering validated instruments, consumables, and standardized workflows that enable high-throughput diagnostics-while others focus on niche clinical applications such as minimal residual disease detection or complex structural variant resolution. Strategic partnerships between technology providers and pharmaceutical developers are increasingly common, aligning companion diagnostic development with therapeutic pipelines to streamline regulatory approval and market access.

Competitive dynamics hinge on the ability to demonstrate analytical validity, clinical utility, and operational scalability. Organizations that invest in rigorous multicenter validation studies and interoperable reporting standards gain credibility with laboratories and payers. In addition, companies that provide end-to-end solutions-including sample logistics, bioinformatics, and clinician-facing interpretation-are better positioned to capture value in hospital and laboratory settings that prefer turnkey implementations.

Mergers, acquisitions, and licensing agreements continue to shape the landscape as firms seek to broaden their portfolios and secure access to complementary technologies and regional distribution networks. Simultaneously, a growing cohort of specialized service providers supports research institutes and pharmaceutical companies with bespoke assay development, biomarker validation, and translational analytics. This ecosystem of platform vendors, service providers, and clinical adopters is creating multiple pathways for innovation diffusion, each with distinct implications for pricing, reimbursement negotiation, and long-term sustainability.

Actionable strategic priorities for leaders to build supply resilience, clinical validation pathways, and interoperable services that accelerate uptake and stewardship of profiling solutions

Industry leaders should prioritize investments that reinforce resilience, clinical relevance, and seamless integration into care pathways. Strengthening supply chain transparency and sourcing flexibility will mitigate tariff and logistics risks, while targeted investments in regional manufacturing or distribution can shorten lead times and stabilize access to critical consumables. Concurrently, organizations should invest in cross-platform validation studies that demonstrate concordance between technologies and support interoperability of clinical reports across electronic health systems.

From a product and clinical strategy standpoint, companies should align assay development with high-impact clinical use cases such as therapy selection and minimal residual disease monitoring, producing evidence packages that address payer and clinician requirements. Collaboration with pharmaceutical sponsors for co-development of companion diagnostics and with academic centers for prospective validation studies will accelerate clinical uptake. Equally important is building interpretive services and decision-support tools that translate complex molecular results into actionable clinical recommendations, reducing adoption friction among clinicians.

Operationally, stakeholders must expand workforce training and establish robust quality systems to sustain reproducibility as testing volumes grow. Leaders should also engage proactively with regulators and payers to shape evidence expectations and reimbursement frameworks, emphasizing real-world performance and patient-centric outcomes. Finally, adopting flexible commercial models-ranging from centralized reference testing to reagent-as-a-service-can help organizations tailor offerings to diverse end-user needs and create multiple revenue streams while maintaining patient access.

A transparent and practitioner-focused methodology combining expert engagements, technical literature synthesis, and cross-validation against laboratory standards to ensure actionable insights

The research methodology underpinning this executive summary combined primary and secondary sources, expert interviews, and structured synthesis to produce a balanced assessment of technological, clinical, and commercial trends. Primary inputs included conversations with laboratory directors, clinical investigators, and industry executives to capture operational realities, evidence requirements, and adoption barriers. These qualitative engagements were supplemented by careful review of peer-reviewed literature, regulatory guidance, and technical white papers to ground technological descriptions and clinical use-case delineations.

Analytic approaches emphasized triangulation: cross-referencing expert perspectives with published validation studies and technical specifications to identify consistent patterns of performance and adoption. Particular attention was paid to assay sensitivity, specificity, and workflow compatibility, as well as to logistics such as sample stability and cold chain dependencies. Where possible, methodological choices were benchmarked against established laboratory standards and consensus recommendations to ensure practical relevance.

Limitations of the methodology include potential bias inherent in selective expert sampling and variability in publicly available technical documentation. To mitigate these constraints, the study prioritized sources with direct operational experience and sought corroboration across multiple stakeholder types. The result is a defensible, practitioner-oriented set of insights designed to support strategic decision-making without relying on proprietary market estimates.

Final synthesis underscoring the critical interplay of technology, evidence, and operational resilience that will determine which profiling approaches achieve sustained clinical impact

In conclusion, cancer profiling is at an inflection point where technical advances, regulatory evolution, and shifting supply chain considerations converge to create both opportunities and operational challenges. The most successful organizations will be those that integrate robust assay technology with validated workflows, responsive supply strategies, and clinician-centered reporting that directly support therapeutic decision-making. Emphasizing cross-platform validation and evidence generation will be critical for translating analytical capabilities into routine clinical use.

Moreover, regional heterogeneity and policy dynamics will require adaptive commercial models and sustained stakeholder engagement. By focusing on resilience, clinical alignment, and partnerships that bridge technological and therapeutic development, leaders can accelerate the adoption of high-impact profiling solutions while safeguarding continuity of care. The insights presented here aim to equip senior decision-makers with the context and priorities needed to navigate this evolving landscape and to identify the investments that will yield enduring clinical and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Profiling Market, by Cancer Type

  • 8.1. Hematologic Malignancies
    • 8.1.1. Leukemia
    • 8.1.2. Lymphoma
    • 8.1.3. Multiple Myeloma
  • 8.2. Solid Tumors
    • 8.2.1. Breast
    • 8.2.2. Colorectal
    • 8.2.3. Lung
    • 8.2.4. Prostate

9. Cancer Profiling Market, by Technology

  • 9.1. Fluorescence In Situ Hybridization
  • 9.2. Immunohistochemistry
  • 9.3. Microarray
  • 9.4. Next Generation Sequencing
    • 9.4.1. Long Read Sequencing
    • 9.4.2. Short Read Sequencing
  • 9.5. Polymerase Chain Reaction

10. Cancer Profiling Market, by Sample Type

  • 10.1. Blood
    • 10.1.1. Plasma
    • 10.1.2. Serum
    • 10.1.3. Whole Blood
  • 10.2. Saliva
  • 10.3. Urine

11. Cancer Profiling Market, by Biomarker Type

  • 11.1. DNA-Based
  • 11.2. Protein-Based
  • 11.3. RNA-Based

12. Cancer Profiling Market, by Application

  • 12.1. Diagnosis
  • 12.2. Monitoring
    • 12.2.1. Liquid Biopsy
    • 12.2.2. Minimal Residual Disease
  • 12.3. Prognosis
  • 12.4. Research
  • 12.5. Therapy Selection
    • 12.5.1. Companion Diagnostics
    • 12.5.2. Pharmacogenomics

13. Cancer Profiling Market, by End User

  • 13.1. Diagnostic Laboratories
  • 13.2. Hospitals
  • 13.3. Pharmaceutical Companies
  • 13.4. Research Institutes

14. Cancer Profiling Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cancer Profiling Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Profiling Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cancer Profiling Market

18. China Cancer Profiling Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. 4basecare Onco Solutions Private Limited
  • 19.6. ACT Genomics Co., Ltd. by Prenetics Global Limited
  • 19.7. Agendia, Inc.
  • 19.8. Agilent Technologies, Inc.
  • 19.9. BostonGene Corporation
  • 19.10. Caris Life Sciences
  • 19.11. Exact Sciences Corporation
  • 19.12. F. Hoffmann-La Roche AG
  • 19.13. GENINUS Inc.
  • 19.14. Genomic Life
  • 19.15. GenScript Biotech Corporation
  • 19.16. Guardant Health, Inc.
  • 19.17. Hologic, Inc.
  • 19.18. HTG Molecular Diagnostics, Inc.
  • 19.19. Illumina, Inc.
  • 19.20. IMBdx, Inc.
  • 19.21. Laboratory Corporation of America Holdings
  • 19.22. Lucence Health, Inc.
  • 19.23. Merck KGaA
  • 19.24. NanoString Technologies, Inc.
  • 19.25. Neogenomics, Inc.
  • 19.26. Nonacus Limited
  • 19.27. OncoDNA S.A.
  • 19.28. Oncompass Medicine Hungary Kft.
  • 19.29. Paragon Genomics, Inc.
  • 19.30. Personalis, Inc.
  • 19.31. Perthera, Inc.
  • 19.32. Qiagen N.V.
  • 19.33. Renovaro Biosciences Inc.
  • 19.34. Strand Life Sciences
  • 19.35. Sysmex Corporation
  • 19.36. Takara Bio Inc.
  • 19.37. Tempus Labs Inc.
  • 19.38. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER PROFILING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER PROFILING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER PROFILING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER PROFILING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER PROFILING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER PROFILING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER PROFILING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CANCER PROFILING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER PROFILING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER PROFILING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER PROFILING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER PROFILING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER PROFILING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER PROFILING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER PROFILING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER PROFILING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER PROFILING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER PROFILING MARKET SIZE, BY BREAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER PROFILING MARKET SIZE, BY BREAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER PROFILING MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER PROFILING MARKET SIZE, BY COLORECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER PROFILING MARKET SIZE, BY COLORECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER PROFILING MARKET SIZE, BY COLORECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER PROFILING MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER PROFILING MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER PROFILING MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER PROFILING MARKET SIZE, BY PROSTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER PROFILING MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER PROFILING MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER PROFILING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER PROFILING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER PROFILING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER PROFILING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER PROFILING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER PROFILING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER PROFILING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER PROFILING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER PROFILING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER PROFILING MARKET SIZE, BY LONG READ SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER PROFILING MARKET SIZE, BY LONG READ SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER PROFILING MARKET SIZE, BY LONG READ SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER PROFILING MARKET SIZE, BY SHORT READ SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER PROFILING MARKET SIZE, BY SHORT READ SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER PROFILING MARKET SIZE, BY SHORT READ SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER PROFILING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER PROFILING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER PROFILING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER PROFILING MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER PROFILING MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER PROFILING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER PROFILING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER PROFILING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER PROFILING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER PROFILING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER PROFILING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER PROFILING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER PROFILING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER PROFILING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER PROFILING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER PROFILING MARKET SIZE, BY DNA-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER PROFILING MARKET SIZE, BY DNA-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER PROFILING MARKET SIZE, BY DNA-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER PROFILING MARKET SIZE, BY PROTEIN-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER PROFILING MARKET SIZE, BY PROTEIN-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER PROFILING MARKET SIZE, BY PROTEIN-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER PROFILING MARKET SIZE, BY RNA-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER PROFILING MARKET SIZE, BY RNA-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER PROFILING MARKET SIZE, BY RNA-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER PROFILING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER PROFILING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER PROFILING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER PROFILING MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER PROFILING MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER PROFILING MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER PROFILING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANCER PROFILING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER PROFILING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER PROFILING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CANCER PROFILING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER PROFILING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CANCER PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS CANCER PROFILING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL CANCER PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. GCC CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 250. GCC CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. GCC CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 253. GCC CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. GCC CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 255. GCC CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. GCC CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. GCC CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 258. GCC CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 259. GCC CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. G7 CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. G7 CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. G7 CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 289. G7 CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 290. G7 CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. G7 CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 292. G7 CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. G7 CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 294. G7 CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. G7 CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. G7 CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 297. G7 CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 298. G7 CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. NATO CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 300. NATO CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. NATO CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 302. NATO CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 303. NATO CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. NATO CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 305. NATO CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. NATO CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 307. NATO CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. NATO CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 309. NATO CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 310. NATO CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 311. NATO CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. GLOBAL CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES CANCER PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA CANCER PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA CANCER PROFILING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)